BioHarvest Sciences Inc. (BHST) launches single-dose VINIA Daily Chews. New single-dose chew format may support incremental consumer adoption and sales growth.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 5.36 | 2.39 | 23.03 | 16.22 |
| Receivables | 1.23 | 1.81 | 2.92 | 4.18 |
| Inventory | 2.47 | 3.66 | 4.56 | 5.78 |
| Other | — | — | — | — |
| 9.05 | 7.86 | 30.50 | 26.18 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 1.78 | 3.53 | 2.63 | 2.75 |
| ST’ Debt | 20.53 | 3.91 | 0.15 | 2.66 |
| Other | 0.53 | 1.14 | 0.45 | 0.46 |
| 26.47 | 14.26 | 7.68 | 11.68 |
| 10y | 5y | 3y | |
| Sales | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡ | ‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 8.51 | 8.84 | — | — |
—
|
| ’25 | 7.86 | 8.52 | 9.07 | 9.07 |
34.51
|
| ’24 | 5.34 | 6.03 | 6.54 | 7.28 |
25.19
|
| ’23 | 2.16 | 2.75 | 3.24 | 4.52 |
12.67
|
| ’22 | 0.70 | 0.84 | 1.52 | 2.44 |
5.50
|
| ’21 | 0.31 | 0.42 | 0.64 | 0.73 |
2.10
|
| ’20 | 0.04 | 0.04 | 0.05 | 0.26 |
0.40
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (1.38) | (2.79) | — | — |
—
|
| ’25 | (1.43) | (1.46) | (2.09) | (2.25) |
(7.23)
|
| ’24 | (1.58) | (0.96) | (1.76) | (2.39) |
(6.68)
|
| ’23 | (1.65) | (2.88) | (0.99) | (2.99) |
(8.52)
|
| ’22 | (2.50) | (1.74) | (2.50) | (2.50) |
(9.24)
|
| ’21 | (1.20) | (1.88) | (1.43) | (2.29) |
(6.79)
|
| ’20 | (0.66) | (0.10) | (1.86) | (1.25) |
(3.87)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (1.97) | (3.36) | — | — |
—
|
| ’25 | (2.11) | (2.05) | (2.52) | (2.91) |
(9.58)
|
| ’24 | (1.80) | (2.67) | (2.27) | (2.78) |
(9.52)
|
| ’23 | (2.03) | (3.24) | (1.43) | (3.28) |
(10.00)
|
| ’22 | (2.89) | (2.06) | (2.78) | (2.77) |
(10.50)
|
| ’21 | (1.46) | (2.40) | (1.93) | (2.64) |
(8.43)
|
| ’20 | (0.67) | (0.11) | (1.87) | (1.40) |
(4.05)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.11) | (0.17) | — | — |
—
|
| ’25 | (0.13) | (0.24) | (0.14) | (0.10) |
(0.60)
|
| ’24 | (0.35) | (0.04) | (0.16) | (0.17) |
(0.80)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 5.85 | 4.03 | 4.66 | 4.72 | — | — | — |
Low Price
|
| — | — | — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 17.50 | 8.19 | 7.70 | 12.80 | — | — | — |
High Price
|
| — | — | — | — | — | — | — | — | 87 | 89 | — | — | — |
Employees
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.29 | 0.39 | — | — | — |
Revenue/Emp
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 5.50 | 12.67 | 25.19 | 34.51 | — | — | — |
Revenue
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 22.17% | 44.45% | 55.35% | 59.34% | — | — | — |
Gross Margin
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (11.24) | (12.56) | (12.90) | (11.06) | — | — | — |
EBT
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (204.37%) | (99.15%) | (51.23%) | (32.05%) | — | — | — |
EBT Margin
|
| — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (11.24) | (12.56) | (12.91) | (11.13) | — | — | — |
Net Income
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.71 | 0.84 | 1.25 | 1.62 | — | — | — |
Depreciation
|
| — | — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.42 | 0.94 | 1.56 | 1.87 | — | — | — |
Revenue/Sh
|
| — | — | — | — | — | — | — | (1.05) | (0.80) | (0.60) | — | — | — |
Earnings/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.71) | (0.63) | (0.41) | (0.39) | — | — | — |
Cash Flow/Sh
|
| — | — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.10) | (0.11) | (0.18) | (0.13) | — | — | — |
Capex/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.80) | (0.74) | (0.59) | (0.52) | — | — | — |
Free CF/Sh
|
| — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.45) | (1.10) | 0.08 | 1.38 | — | — | — |
Book Value/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 13.07 | 13.53 | 16.19 | 18.41 | — | — | — |
Shares
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
PE Ratio
|
| — | — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 17.23 | 5.98 | 3.97 | 2.77 | — | — | — |
PS Ratio
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | 0.00 | 0.00 | 75.25 | 3.75 | — | — | — |
PB Ratio
|
| — | — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 18.47 | 7.18 | 4.03 | 2.18 | — | — | — |
EV/Sales
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (9.67) | (9.10) | (10.67) | (7.84) | — | — | — |
EV/FCF
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (9.24) | (8.52) | (6.68) | (7.23) | — | — | — |
Op' Cash Flow
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.26) | (1.47) | (2.83) | (2.35) | — | — | — |
Capex
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (10.50) | (10.00) | (9.52) | (9.58) | — | — | — |
FCF
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (7.20) | (17.41) | (6.40) | 22.82 | — | — | — |
Working Cap'
|
| — | — | — | ‡‡‡‡‡ | — | — | 8.55 | 20.53 | 3.91 | 2.57 | — | — | — |
Total Debt
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 6.81 | 15.18 | 1.52 | (20.46) | — | — | — |
Net Debt
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (5.93) | (14.85) | 1.33 | 25.45 | — | — | — |
Sh' Equity
|
| — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (114.65%) | (103.00%) | (64.56%) | (30.65%) | — | — | — |
ROA
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | (750.28%) | (1,916.54%) | (153.54%) | (69.80%) | — | — | — |
ROIC
|
| — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | 731.03% | 120.91% | 190.98% | (83.17%) | — | — | — |
ROE
|
BioHarvest Sciences Inc. (BHST) has engineered a biotech breakthrough, harnessing proprietary plant-cell technology to produce high-value nutraceuticals and pharmaceuticals sustainably—without traditional farming. Revenue has skyrocketed from a mere $218,000 in 2019 to $25.2 million in 2024, delivering a jaw-dropping 11,454% surge and over 150% CAGR, fueled by scaling operations, 87 new employees boosting productivity to $289K per head, and gross margins leaping from 13% to 55%. This positions BHST at the vanguard of agritech disruption amid booming demand for eco-friendly bio-actives.
Despite profitability hurdles—with net losses at $12.9 million in 2024—key metrics scream progress: EBT margins improved 97% to -0.51%, debt slashed 81% to $3.9 million, and free cash flow per share turned 43% less negative. Stock volatility reflects biotech drama, from $0.05 lows to a $67.90 peak and now trading at attractive 4x sales (down 95% from frothy highs), undervalued versus peers.
Analysts are buzzing with 150-190% upside targets, betting on margin expansion to 60%+, capacity ramps, partnerships, and macro tailwinds like rate cuts and ESG mandates. BHST’s resilient trajectory hints at a profitability inflection—perfect for growth seekers eyeing the next biotech multibagger.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.